HURAConference•prnewswire•
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
Sentiment:Neutral (40)
Summary
TAMPA, Fla., Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present at the 27th Annual H.C. Wainwright...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 20, 2025 by prnewswire